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June 11, 2019 — In 2009, a novel H1N1 influenza (flu) virus emerged to cause the first flu
pandemic in 40 years. The 2009 H1N1 pandemic was estimated to be associated with
151,700 to 575,400 deaths worldwide during the first year it circulated. [1] This H1N1 virus
has continued to circulate seasonally to this day. CDC and its many partners have made great
strides in the fields of influenza surveillance, prevention, and treatment since 2009, benefiting
both the annual response to seasonal flu epidemics, as well as the global capacity to respond
to the next pandemic. Key improvements are summarized on the pages below.
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CDC’s Kits Changed the Game in 2009
When the pandemic H1N1 virus emerged in April 2009, laboratories were quickly
overwhelmed by sharp increases in testing demands.
CDC moved quickly to expand domestic and global capacity to detect the virus by using its
genetic sequence data to update existing rRT-PCR test kits.
Less than two weeks after the novel H1N1 virus was identified, revised CDC rRT-PCR test kits
began shipping to public health laboratories through an FDA Emergency Use Authorization
(EUA). Once labs had the CDC test kit and verified that their testing was running properly,
they were able to process their own specimens and no longer needed lab confirmation from
CDC.
Gene sequencing technology
During the pandemic, owing in part to the preparedness work done prior to 2009, CDC and
public health laboratories were able to use molecular testing technology, “with its pinpoint
accuracy and revolutionary speed” [2] to detect cases, and monitor the spread of the virus
and its characteristics, including watching for emerging drug resistance, for example. In the
wake of the 2009 pandemic, numerous retrospective analyses deemed the use of this
technology to be one of the response’s key successes [3].
Since the pandemic, CDC’s ability to map the complete influenza virus genome has improved
exponentially, thanks to considerable leaps forward in gene sequencing technology,
sometimes referred to as Next Generation Sequencing or Advanced Molecular Detection
(AMD) technology. Where previous technologies revealed the genes of the predominant
influenza virus in a respiratory specimen, it’s now possible to see the gene sequences of all of
the influenza particles in a single specimen, thereby giving deeper insight into how influenza
viruses may change, for example, by mutating inside a single patient to become resistant to
antiviral drugs.
In 2012 CDC’s influenza laboratory transitioned from a characterization-first approach to a
sequence-first approach so now all flu viruses undergo full sequencing as a first step when
they arrive at CDC. This change has reduced public health response time to flu outbreaks and
also served to greatly expand the global repositories of influenza gene sequence data.
Meanwhile, ongoing technological improvements by device manufacturers and CDC’s
innovative protocols have brought the gene sequencing cost per virus down from about
$180.00 in 2012 to $25.00 per virus in 2019, with additional improvements in the works to
bring the cost down even further.
In 2009, CDC sequenced influenza virus genomes primarily for the identification of vaccine
reference viruses. Now, CDC performs “next generation sequencing” on close to 7,000
influenza viruses annually, and has submitted more than 30,000 flu virus genomes to public
databases.
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Influenza public health laboratory tests
RT-PCR
Since 2009, the widespread adoption by public health laboratories of the testing technique
called “real-time Reverse Transcription-Polymerase Chain Reaction” (rRT-PCR) with CDC’s flu
rRT-PCR test kits has directly enhanced the nation’s pandemic preparedness in a number of
ways. For one, widespread use of both has led to standardization of influenza testing across
the nation’s public health laboratories. Relative to the other diagnostic methods widely used
by laboratories to reveal the type and subtype of flu virus in a sample, rRT-PCR produces
more-reliable results, and produces those results faster than most other laboratory
techniques. [4]
CDC’s primary rRT-PCR test for influenza viruses (called the ‘CDC Human Influenza Virus
Real-Time RT-PCR Diagnostic Panel’) is an internationally recognized reference method for
detection of influenza. This means the performance of other detection methods is often
measured against the performance of CDC’s rRT-PCR flu test.
The adaptability of the rRT-PCR test allows laboratories to quickly adjust how specimens are
processed in outbreak and pandemic situations to avoid backlogs and unnecessary use of
resources. CDC provides algorithms that help to ensure that as more specimens are tested,
reagents are conserved, thereby maximizing their public health benefit and further reducing
the possibility of supply shortages.
Although laboratories have the option of using other rRT-PCR tests, use of the CDC test in
lieu of commercially manufactured rRT-PCR tests takes the pressure off individual
laboratories of ensuring their tests are able to detect the newest emerging viruses.
CDC uses gene sequence data to update its influenza diagnostic kits and reagents, which are
used around the world by public health laboratories as the gold-standard for detecting
influenza, in large part because of CDC’s rapid response in updating the kits and reagents
each time a novel virus emerges.
For example, in 2012 the U.S. experienced a rapid up-tick in human infections with swine
influenza viruses (called variant virus infections) associated with exposure to infected pigs.
CDC quickly confirmed the CDC rRT-PCR test kit’s ability to detect those swine viruses
appearing in people, and then issued guidance to laboratories on how to interpret rRT-PCR
test results when testing specimens from patients with known pig exposure. Since then, CDC
has monitored how the diagnostic kit has performed in detecting variant infections and has
updated guidance and virus-specific assay materials (called reagents) to make sure the tests
are able to detect these viruses as they have evolved.
In April 2013, shortly after the first influenza A(H7N9) human infections in China were reported
and within days of China CDC sharing gene sequences of the H7N9 virus, U.S. CDC quickly
modified and then quality-checked CDC’s existing H7 rRT-PCR test and drafted protocols
and guidance for its use. On April 22, 2013, the U.S. Food and Drug Administration (FDA)
issued an Emergency Use Authorization and the H7 rRT-PCR test with test components and
CDC guidance were made available to public health laboratories so they would be able to test
for H7N9 viruses too.
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International Reagent Resource
While RT-PCR is fast and accurate, it requires a steady stream of laboratory supplies called
reagents (primers, probes and enzymes) to perform testing, which can become scarce or
costly during outbreaks when testing demands increase.
To address this potential shortcoming, in 2008 CDC established the Influenza Reagent
Resource (IRR) as a warehouse for CDC-developed influenza supplies that laboratories need
to carry out basic research; develop diagnostics, vaccines and drugs; and conduct
surveillance for emerging influenza threats. During the pandemic, the IRR proved to be a
critical resource in terms of providing domestic and international laboratories with the
supplies needed to test for the new 2009 H1N1 virus.
Ten years later, the IRR is firmly established as a central component of influenza research,
surveillance and diagnostic testing in the United States. Further, it also has been expanded to
include production and distribution of additional CDC-developed reagents for a wider range
of pathogens that are within the scope of the National Center for Immunization and
Respiratory Diseases (NCIRD).Some of the newer additions include reagents for respiratory
syncytial virus (RSV), Middle Eastern Respiratory Syndrome (MERS-CoV), meningitis, and
Streptococcus pneumoniae. The program’s broader scope is reflected in a new name, the
International Reagent Resource.
With regard to pandemic preparedness, public health laboratories across the globe continue
to use the reagents they receive from the IRR for surveillance of novel influenza viruses (such
as H7N9 and H5N1) in tandem with the World Health Organization (WHO) Global Influenza
Surveillance and Response System (GISRS).external icon For influenza and other pathogens,
CDC’s subject matter experts provide technical guidance and oversight to ensure that IRR
acquires, authenticates, manufactures and distributes quality-controlled reagents that support
global surveillance efforts.
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Advances in Tests Used in Clinical Settings
Compared to ten years ago, clinicians now have more tests available for detection of
influenza viruses in respiratory specimens, including a wider selection of highly accurate
molecular assays (some rapid, some not), and improved rapid influenza antigen detection
tests (RIDTs).
Rapid and accurate diagnosis of influenza virus infection facilitates timely patient
management for seasonal influenza as well as pandemic influenza. Influenza testing has been
used to inform decisions on the use of antiviral drugs for treatment, to avoid misuse of
antibiotics for treatment, and to reduce the need for other diagnostic tests. Influenza testing
also can be helpful in informing recommendations for sick people living with others who are at
high risk of developing serious influenza complications. See Guide for considering influenza
testing when influenza viruses are circulating in the community for more information.)
The need for better rapid influenza tests and clear rapid test guidance for clinicians became
apparent during the 2009 H1N1 pandemic, when false-negative rapid antigen detection test
results contributed to delays and missed opportunities in treating pandemic flu virus-infected
patients with antiviral drugs; and delays in implementing infection control measures for such
patients. [5]
Shortly after the pandemic, CDC and partners began working to address issues with rapid
antigen detection tests available at the time, reaching an important milestone in 2017 when
rapid influenza antigen detection tests (RIDTs) were reclassified by FDA (described in more
detail, below) and held to higher standards.
In June 2014, a new kind of rapid influenza test was approved by FDA (the Alere (TM) i
Influenza A&B test by Alere Scarborough, Inc D/B/A Binax, Inc, now owned by Abbott and
called the ID NOWTIM Influenza A&B) external iconwhich detects flu A and B viruses by
detecting the PB2 flu virus gene in respiratory specimens. This approval marked the
beginning of a new category of tests, referred to as rapid influenza molecular assays.
Rapid influenza molecular assays are a relatively new type of influenza diagnostic test. These
tests are similar to RT-PCR (which is also a molecular process and currently the gold standard
for influenza virus detection), in that both tests use nucleic acid amplification, which detects
influenza viruses in a respiratory specimen by amplifying (multiplying) certain nucleic acids
(building blocks of genes) in the influenza virus genome.
Since 2014, other rapid influenza molecular assays have been approved by FDA and are
available for use in clinical settings. Of those, some are approved for point-of-care or bedside
use, and do not require a clinical laboratory, including Cobas® Influenza A/B and Cobas®
Influenza A/B RSV Assay by Roche Molecular Diagnostics; Xpert Xpress Flu and Xpert Xpress
Flu/RSV by Cepheid; Accula Flu A/Flu B assay by Mesa Biotech Inc,; and ID Now TM by
Abbot.
Rapid influenza molecular assays have a strong ability to identify correctly patients with
evidence of influenza virus infection (referred to as high sensitivity, greater than 90%) and a
strong ability to identify correctly patients without evidence of influenza virus infection,
referred to as high specificity (90-100%). These assays produce results in 15 to 30 minutes,
making them a convenient option for clinical management of patients. Other rapid influenza
molecular assays (such as the Cobas® Influenza A/B & RSV Assay by Roche Molecular
Diagnostics) are approved that detect influenza A and B viruses and respiratory syncytial virus
(RSV) in respiratory specimens. These tests are particularly useful in the clinical management
of young children with acute respiratory illness, but can be used for persons of all ages.
Additionally, a number of other influenza molecular assays are FDA-approved, for use in a
moderately complex or complex hospital clinical laboratory. These assays may take more
than one hour to produce results. Many of these molecular assays detect influenza A and B
viruses as well as other respiratory viruses such as adenovius, coronavirus, human
metapneumovirus, human rhinovirus/enterovirus, parainfluenza virus, and RSV. Some also
detect some respiratory bacterial infections.
Both rapid molecular and other molecular assays are more accurate than previously available
influenza tests for use in clinical settings. These advances in molecular technology provide
more-accurate influenza testing results and are likely to improve clinical management of
patients with suspected influenza in ambulatory care clinics and emergency departments, and
in hospitalized patients as well.
With regard to rapid influenza antigen detection tests (RIDTs), to address the issues identified
during the pandemic, in 2011 the CDC, the Joint Commission, the Biomedical Advanced
Research and Development Authority (BARDA), the Medical College of Wisconsin (MCW) and
other public and private partners addressed key RIDT-related issues by:
Creating the first method for systematically evaluating commercially available RIDTs,
described in a 2012 Morbidity and Mortality Weekly Report (MMWR) article
Enhancing awareness among clinicians of appropriate RIDT protocols with new
courses, videos and decision-making tools, and;
Working with FDA to reclassify RIDTs from Class I to Class II with Special Controls,
thereby holding current and new RIDTs to higher performance standards.
Reclassification means that RIDTs are now subject to the following requirements [6]:
Manufacturers must test their RIDTs annually to ensure they can detect currently
circulating seasonal flu viruses. RIDTs with lower sensitivity to those flu viruses will
need to indicate so on their labeling.
RIDTs must meet minimum performance criteria, such as high sensitivity and high
specificity to detect flu viruses in respiratory specimens compared to RT-PCR or viral
culture. This means that currently FDA-approved RIDTs will now be more accurate in
detecting flu viruses in respiratory specimens than previous RIDTs.
In the event of a pandemic, manufacturers must test the reactivity of their RIDTs with
the newly emergent flu virus as soon as virus samples become available.
Since 2017 when reclassification of RIDTs occurred, manufacturers have made
positive, steady changes to rapid influenza antigen detection tests, but more work still
needs to be done.
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Surveillance
Right-sizing initiative
The massive amount of laboratory testing that occurred during the 2009 H1N1 pandemic
provided an opportunity for researchers to identify the optimal levels of influenza surveillance
and laboratory testing needed in the United States, including ways to improve efficiency.
To answer those questions, in 2010, CDC and the Association of Public Health laboratories
(APHL) began developing a “right-size” approach to influenza virologic surveillance which was
based on extensive input from public health laboratories and stakeholders. Since then, this
right-size approach has helped public health laboratories to:
standardize virologic surveillance practices, determine the optimal number of
specimens to test to produce statistical confidence in resulting data, and define public
health surveillance priorities;
adopt requirements, resources and statistical calculators that aid in planning and
justifying budget and resource requests;
increase the understanding and support from political leaders and the public;
speak a common language between laboratories and epidemiologists; and
assist decision makers in analyzing the impacts of budget decisions on national
surveillance objectives, especially with regard to pandemic preparedness capacity.
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Automated transmission of laboratory reports
In addition to identifying the optimum “sampling” strategy, major improvements in sharing this
data have taken place. In March 2010, five laboratories were routinely sharing data
electronically with CDC. Today, all public health laboratories at the state level and some local
public health and clinical laboratories send data electronically to CDC’s Influenza Division This
increase has improved the timeliness and completeness of reporting, for both seasonal
influenza surveillance activities and the identification of novel influenza A viruses.
Incorporation of NCHS mortality data
In collaboration with the National Center for Health Statistics (NCHS), since the 2015-2016 flu
season CDC’s Influenza Division has used mortality data collected from death certificates and
reported to NCHS as the principal tool to track influenza-associated mortality in the United
States.
The shift to NCHS data marked a significant advance in the capacity to track flu mortality,
owing in part to efforts made by NCHS to improve the timeliness of jurisdiction reporting and
modernize the infrastructure of national vital statistics, all of which resulted in a system
capable of supporting near real-time surveillance of most deaths in the United States.
The new system presents deaths by the date of occurrence rather than by the date on which
deaths were registered. It also provides a consistent case definition and covers nearly all
deaths occurring in the United States, which is an improvement over the previous (now
retired) system which accounted for only 25 percent of all US deaths.
Inclusion of electronic data in ILINet
CDC’s U.S. Outpatient Influenza-Like Illness Surveillance Network (ILINet) collects data each
week from up to 3,500 outpatient health care providers across all 50 states, Puerto Rico, the
District of Columbia and the U.S. Virgin Islands. Each week, these health care providers report
the total number of patients seen, and the number of patients seen with influenza-like illness
(ILI), by five age groups. The process of reporting numbers of total patients and ILI patients
was labor-intensive, sometimes leading to reporting delays and dips in participation. Since
the pandemic, more ILINet providers have used electronic health records in determining ILI
and patient visits, thereby reducing the reporting burden and providing more-comprehensive,
efficient and timely surveillance. ILINet now captures more patient visits: during the 2018-19
season, more than one million patient visits were reported weekly, almost double the number
of patient visits reported weekly during the 2009 pandemic.
Antiviral resistance testing
Another step forward in surveillance is the number of public health laboratories in the U.S.
that test for resistance to influenza antiviral medications, which increased from four
laboratories before the 2009 H1N1 pandemic to 20 laboratories in 2019. This improvement
was accomplished through training courses, site visits, technical and other support from
CDC. In addition, four laboratories are now able to conduct advanced testing for antiviral drug
resistance, using a more sensitive and complex procedure. Since 2018, CDC’s influenza
laboratories have been testing seasonal and animal viruses for susceptibility to the newest
anti-influenza drug – baloxavir marboxil (Xofluza) and a CDC-developed assay is now being
implemented at the public health laboratory designated for antiviral testing (NIRC, Albany NY).
Lastly, in collaboration with a World Health Organization (WHO) expert group, reference
laboratory materials for detection and reporting of influenza drug resistance have been
developed and shared with laboratories around the world.
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The Burden of Influenza
During the pandemic, influenza hospitalization rates increased, particularly among groups of
people at high risk of developing serious flu complications.
The Influenza Hospitalization Surveillance Network (FluSurv-NET) conducts population-based
surveillance for laboratory-confirmed influenza-related hospitalizations in children and adults.
It has provided critical data for:
informing policy and decision making, especially with regard to vaccine and antiviral
prioritization;
evaluating the effectiveness and safety of pandemic vaccine; and,
identifying groups at high risk for severe flu complications.
Over the course of the pandemic, CDC refined and revised its hospitalization surveillance
methods, eventually developing a way to use FluSurv-NET data to estimate the range of 2009
pandemic flu illnesses, hospitalizations and deaths (also referred to as ‘estimates of flu
burden’) in the United States.
Since the 2009 pandemic, this method of estimation has been applied at the end of each flu
season as a means of illustrating the national impact of seasonal flu. In 2019, CDC also began
providing on a weekly basis preliminary estimates of the burden of influenza during flu
season.
Burden of influenza averted through vaccination
CDC also developed estimates of the number of flu illnesses, hospitalizations and deaths
prevented by flu vaccination each flu season. These estimates are made with mathematical
models that combine illness rates, vaccine coverage, and vaccine effectiveness, to estimate
the amount of flu that would have occurred without flu vaccination. The amount of flu that
was prevented by vaccination was the difference between what would have occurred and
what was estimated to have actually occurred. CDC has continued to estimate the benefits of
influenza vaccination each season. Now, CDC and its partners are better able to
communicate the benefits of flu vaccination and provide clear evidence on the public health
impact that vaccination can have in reducing flu illness.
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Vaccine effectiveness monitoring
While FluSurv-NET provided vaccine effectiveness (VE) data during the 2009 H1N1 pandemic,
the US Flu VE Network has yielded in-depth data about how well flu vaccines are working
each flu season since its inception in 2005.
Seasonal VE data are instrumental in making vaccine policy decisions and improving virus
selection to update the composition of seasonal vaccines. VE data are also pivotal to
understanding the epidemiology and severity of pandemic and seasonal influenza and to
mounting an appropriate responses.
Following the pandemic, multiple improvements were made to the US Flu VE Network
including expanding the number of sites, increasing enrollment, improving the timeliness of
data collection and reporting, and building an infrastructure for conducting special studies to
improve the benefits of vaccines. In addition, in 2016-17 CDC established the Hospitalized
Adult Influenza Vaccine Effectiveness Network (HAIVEN), which focuses on VE among
severely ill adults, as opposed to VE among persons seen as outpatients.
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With regard to available data, at the time of the pandemic, VE studies had shown that
influenza vaccination reduced the risk of mild or moderately severe influenza by
approximately half among children and adults, but there were gaps in knowledge about how
well the vaccine worked in preventing lab-confirmed influenza among pregnant women and in
preventing life-threatening influenza among children and adults.
VE data directly influence policymakers’ decisions regarding influenza vaccination policy both
in the United States and in other countries, so over the last 10 years CDC has created
partnerships and funded research to address major VE knowledge gaps, all with an eye
toward advancing vaccination efforts in the U.S. and internationally.
Pregnant Women
The first CDC-funded study to address these gaps, which was also the first to use laboratory-
confirmed influenza outcomes to assess VE among pregnant women, was published in the
journal Clinical Infectious Diseases in January 2014. This study, which looked at Kaiser
Permanente health plan members in two regions, showed that influenza vaccination reduced
their risk of flu illness by half during 2010 to 2012, indicating that flu vaccine works about as
well in pregnant women as in other young, healthy adults. The study showed influenza
vaccine effectiveness estimates among pregnant women were similar to those found in other
studies among young adults, which ranged from 44% to 51% from 2010 to 2012.
See Study Finds Flu Vaccine Reduces Risk of Flu Illness in Pregnant Women by Half for more
information.
The second CDC-funded study was published in Clinical Infectious Diseases in October 2018:
it was the first study to show that vaccination protects pregnant women against flu-
associated hospitalization.
To conduct this study, CDC partnered with a number of other public health agencies and
health care systems in Australia, Canada, Israel, and the United States through the Pregnancy
Influenza Vaccine Effectiveness Network (PREVENT), which consists of health care systems
with integrated laboratory, medical, and vaccination records. Sites retrospectively examined
medical records of more than two million women who were pregnant from 2010 through 2016
to identify those who were hospitalized with laboratory-confirmed flu.
Key findings of this study include the following:
Over the course of six flu seasons, getting a flu shot reduced a pregnant woman’s risk
of being hospitalized from flu by an average of 40 percent.
More than 80 percent of pregnancies overlapped with flu season, underscoring the
likelihood that pregnant women will be exposed to flu at some point during their
pregnancy.
Flu vaccine was equally protective for pregnant women with underlying medical
problems such as asthma and diabetes, which also increase the risk of serious
medical complications including a worsening of those chronic conditions.
Flu vaccine was equally protective for women during all three trimesters.
See Flu Vaccine Reduces Risk of Flu Hospitalization Among Pregnant Women for more
information.
Children and Adults:
In March 2014 another critical gap was filled, when the first study to estimate VE in children
against flu admissions to pediatric intensive care units (PICUs) was published in the Journal
of Infectious Diseases. CDC researchers found that getting a flu vaccine reduces a child’s risk
of flu-related intensive care hospitalization by 74%, illustrating the important protection flu
vaccine can provide to children against more-serious flu outcomes.
Researchers analyzed the medical records of 216 children age 6 months through 17 years
admitted to 21 PICUs in the United States during the 2010-2011 and 2011-2012 flu seasons.
Though flu vaccination was associated with a significant reduction in risk of PICU admission,
flu vaccine coverage was relatively low among the children in this study: only 18 percent of flu
cases admitted to the ICU had been fully vaccinated.
More than half (55 percent) of PICU cases had at least one underlying chronic medical
condition that placed them at higher risk of serious flu-related complications.
See New Study Shows Flu Vaccine Reduced Children’s Risk of Intensive Care Unit Flu
Admission by Three-Fourths for more information.
In August 2018, a CDC-supported study published in Vaccine was the first to provide
statistically significant VE estimates for adults against hospitalization and admission to ICU.
The study was conducted over four flu seasons from 2012 to 2015 and found that flu
vaccination prevented severe disease:
Flu vaccination among adults reduced the risk of being admitted to the hospital with
flu and placed in a general ward bed by 37 percent.
Flu vaccination was even more effective in preventing the most severe forms of flu and
reduced the risk of being admitted to an ICU with flu by 82 percent.
Because flu vaccine varies in how well it works and people who are vaccinated may still get
sick, the study also looked at whether flu vaccination reduced the severity of illness among
hospitalized people who were vaccinated compared to those who were unvaccinated and
found that:
Among adults who were admitted to the hospital with flu, vaccinated adults were 59
percent less likely to have very severe illness resulting in ICU admission than those
who had not been vaccinated.
Among adults in the ICU with flu, vaccinated patients on average spent 4 fewer days in
the hospital than those who were not vaccinated previously.
The study was a collaborative project with CDC, conducted through the Southern
Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance project, which
prospectively enrolled hospitalized adults 18 years and older from 2012 to 2015 in Auckland,
New Zealand. Eligible hospitalized patients were those who had an overnight admission with
acute respiratory illness. Once enrolled in the study, patients self-reported their flu vaccination
status and were tested for flu infection by RT-PCR.
See Study Shows Flu Vaccine Reduces Risk of Severe Illness for more information.
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In February 2018, the complex process of making CVVs for avian H5 and H7 influenza viruses
was streamlined by the Federal Select Agent Program with its decision to remove the
requirement for live bird lethality testing.
H5 and H7 avian influenza viruses are classified as Select Agents until it is shown that the
viruses are low-pathogenic (unable to cause disease and mortality in chickens in a laboratory
setting).
Previously, live bird lethality testing was used to determine whether an avian influenza CVV
was highly pathogenic or low pathogenic, and thus if it should managed as a Select Agent.
Now, H5 and H7-derived CVVs no longer need to be tested in live birds to show low
pathogenicity. Instead, other data may be submitted in lieu of bird lethality testing.
The Federal Select Agent Program is managed jointly by the Division of Select Agents and
Toxins at the CDC, and the Agriculture Select Agent Services at the Animal and Plant Health
Inspection Service.
Prevention
Influenza Vaccines
CDC and its partners have made significant progress in influenza surveillance; diagnostics;
characterizing viruses for vaccine strain selection; and developing systems to evaluate the
effectiveness of influenza vaccines over the last ten years.
For example, with regard to vaccine development, by using newer production technologies
CDC can now identify and provide candidate vaccine viruses for novel influenza threats to
manufacturers within a matter of weeks.
This and other improvements have helped to better protect the public from seasonal and
pandemic influenza threats through vaccination. However, to more fully protect Americans
from seasonal and pandemic flu, more effective vaccines are needed and more people still
need to receive annual flu vaccines.
In line with that public health mission, more doses of seasonal vaccines and different vaccine
products are available than ever before. In addition to trivalent inactivated vaccine and live
attenuated influenza vaccine, the following vaccines have been approved by the FDA and are
now available:
a high dose vaccine that is designed specifically for people 65 and older to help create
a stronger antibody response;
a trivalent flu vaccine made with adjuvant (an ingredient added to vaccine that helps
create a stronger immune response), which was approved for people 65 years of age
and older;
the first U.S.-approved cell-based flu vaccine, which can potentially be made more
quickly than traditional egg-based vaccines and does not require a large supply of
eggs to produce;
quadrivalent (four component) flu vaccines that protect against both lineages of
influenza B viruses thus offering expanded protection against circulating influenza
viruses; and,
recombinant influenza vaccines, which do not require an egg-grown vaccine virus or
eggs to produce, and which may be manufactured more quickly than egg-based
vaccines.
CDC is currently exploring new ways to further improve influenza vaccine through the
influenza vaccine improvement initiative (iVii). The initiative includes two primary goals.
Goal 1: Build the evidence base for developing more-effective influenza vaccines, and
increase the impact of vaccines that are currently available.
This goal points to the need for deeper data, so during the 2018-19 season, CDC increased
the number and scope of VE Network participants by over 1,500 children and adults, bringing
the total number of participants enrolled to more than 10,500.
CDC also is increasing the diversity of people who can be enrolled in studies and has
expanded VE monitoring through innovative use of health care and other data sources
outside of the US Flu VE Network. The laboratory process of evaluating vaccine response
through the use of enhanced serologic and cellular testing has also been improved.
Goal 2: Increase the capacity of CDC laboratories to select, develop, evaluate and perform
virus characterization to provide candidate vaccine viruses.
To accomplish this, CDC is employing state-of-the-art technologies to increase the volume of
laboratory testing being done. CDC also is working on developing new assays for
manufacturers and regulatory laboratories, and planning evaluation projects that support
vaccine improvement.
CDC also is focusing on expanding and improving global virus detection, and improving
vaccine effectiveness monitoring. This is being done through the expansion of Next
Generation Sequencing and fully transitioning to the Sequence-First initiative described
earlier. In the process, CDC has also worked with partners to automate the pipeline used to
produce, store and share the enormous volume of NGS data.
CDC also is piloting an advanced laboratory strategy to identify viruses, using antigenic data
that are likely to predominate in the human population in future influenza seasons.
CDC meets regularly with vaccine manufacturers and other WHO Collaborating Centers and
Essential Regulatory Laboratories including FDA’s Center for Biologics Evaluation and
Research to share information on a number of vaccine-related topics.
Topics include the availability of candidate vaccine viruses for use in the development and
production of seasonal influenza vaccines, the availability of protocols and reagents needed
for the development, standardization, and regulation of influenza vaccines, and to discuss
potential issues related to the timely production of seasonal influenza vaccines. The group
meets from the time the vaccine composition is announced until vaccines are released for
distribution to health care providers, for both the northern and southern hemisphere influenza
seasons.
Separately, frequent Flu Risk Management Meetings serve as a venue to discuss issues
relating to the U.S. Department of Health and Human Services (HHS) response to seasonal
and pandemic influenza. Subjects for discussion include but are not limited to seasonal
surveillance updates, effectiveness of influenza vaccines, vaccine and antiviral stockpiles,
emerging influenza virus surveillance, clinical trial response to influenza outbreaks of novel
influenza viruses, and pandemic preparedness.
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When a pandemic influenza A virus emerges – like H1N1 in 2009 – well-matched vaccines
may not be available for 6 months or longer, and antiviral medications may be reserved for
treatment and be in short supply because of high demand.
The goals of community mitigation measures are to delay the spread of the disease and
reduce the impact of an influenza pandemic in U.S. communities.
Community mitigation measures are often referred to as Non Pharmaceutical Interventions (or
NPIs), and include actions other than use of vaccines and medications that people and
communities can take to help slow the spread of a pandemic influenza virus.
Community Mitigation Measures
Community Mitigation Guidelines to Prevent Pandemic Influenza – United States, 2017
Based on lessons learned from the 2009 H1N1 pandemic response and an expanded
contemporary NPI evidence base, CDC published updated pre-pandemic planning guidelines
– Community Mitigation Guidelines to Prevent Pandemic Influenza – United States, 2017 – in
MMWR Recommendations and Reports on April 21, 2017. The guidelines offer free CE credits
for healthcare and public health practitioners, and are available at
https://www.cdc.gov/mmwr/volumes/66/rr/pdfs/rr6601.pdfpdf icon.
The 2017 guidelines summarize key lessons learned from the 2009 H1N1 pandemic
response; encourage state and local public health officials to plan and prepare for
implementing NPIs early in an influenza pandemic in community settings; describe new or
updated pandemic planning and assessment tools; and provide the latest scientific findings
to support updated recommendations on the use of NPIs to help slow the spread and
decrease the impact of an influenza pandemic. The 2009 H1N1 pandemic response
highlighted that pre-pandemic planning and preparedness – from local to federal levels –
must be broad, flexible, and multi-sectoral, and emphasized the critical value of public
engagement and community preparedness – including families, schools, and businesses – for
successful NPI implementation during a pandemic. Research conducted during and in the
wake of the 2009 H1N1 pandemic documented that public acceptance of NPIs in the United
States is generally high, even for disruptive measures like school closures. These findings
underscore the importance of pandemic preparedness at all levels of society to ensure timely
implementation of community mitigation measures from the onset of a future pandemic, when
these measures may be the only tool available in many jurisdictions.
To help implement the 2017 guidelines and to assist states and localities with pre-pandemic
planning and decision-making in their communities, CDC also published online six plain-
language, pre-pandemic NPI planning guides for various audiences and community settings:
households, educational settings, workplace settings, community- and faith-based
organizations serving vulnerable populations, event planners of large/mass gatherings, and
health communicators in community preparedness. The six guides are available.
CDC continues to conduct and support research to assess the feasibility, acceptability, and
effectiveness of NPI implementation in various community settings. Select NPI research
references, as well as additional NPI communication, education, and training materials, are
available at CDC’s dedicated NPI website.
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Treatment
The number of available, approved and recommended treatment options has increased in the
last ten years.
During the 2009 H1N1 pandemic, the influenza antiviral medication oseltamivir (oral
oseltamivir, available under the trade name Tamiflu®) was used extensively for treatment,
while zanamivir (inhaled, trade name Relenza®) was used less.
Oral oseltamivir’s widespread use was due to it being approved, recommended and utilized
for treatment of patients hospitalized with severe influenza. It also was recommended for use
in hospitalized patients with non-severe influenza, although no antiviral medications were
approved by FDA for use in that group.
Outpatients could be prescribed either oral oseltamivir or inhaled zanamivir, which were both
approved for early treatment of uncomplicated influenza by FDA.
Of the two medications, CDC was more concerned with the possibility of resistance emerging
against oseltamivir, which did happen, but not often. The oseltamivir-resistant viruses that did
emerge were not transmitted easily from person to person, and zanamivir was used effectively
to treat them.
Beginning in April 2009 and continuing for a few years after the pandemic, the FDA’s
Emergency Investigational New Drug (EIND) program provided an application process which
authorized investigational use of IV zanamivir for patients with severe and life-threatening
influenza.
Later, on October 23rd, 2009, FDA issued an Emergency Use Authorization (EUA) for IV
Peramivir. At the time, IV Peramivir was an investigational intravenous antiviral drug used
rarely to treat people who had been hospitalized with severe influenza. The drug was held in
the Strategic National Stockpile (SNS) and distributed by CDC under the EUA. Licensed
clinicians were able to request this product through the CDC website electronic request
system, and product was delivered directly to hospital facilities until June 2010 when the EUA
was terminated.
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Following the pandemic, in December 2014, IV Peramivir was approved by FDA for early
treatment of uncomplicated influenza in outpatients, which also opened up some off-label use
in treating influenza in hospitalized patients. Previously, with the exception of the IV Peramivir
EUA during the pandemic, oseltamivir and zanamivir were the only recommended antiviral
medications for treatment of influenza. (The other approved antiviral drugs – amantadine and
rimantadine – were not and are still not recommended due to high levels of resistance
detected in circulating influenza viruses).
Roughly three years later, in September 2017, FDA approved the first generic version of
oseltamivir.
Oseltamivir, zanamivir and IV peramivir are all neuraminidase-inhibitor influenza antiviral
medications, so named because each works by targeting the neuraminidase surface protein
of the influenza virus to stop the virus from being released from infected cells and spreading
to healthy cells.
In December 2018, a new influenza antiviral medication called oral baloxavir marboxil (trade
name Xofluza®) was approved by FDA and is recommended for treatment of influenza.
Baloxavir works differently, primarily by preventing an influenza virus from multiplying when it
is inside a cell. Because baloxavir works differently, it is in a new class of antiviral medications
called cap-dependent endonuclease inhibitors. Like the neuraminidase-inhibitor medications,
baloxavir has activity against both influenza A and B viruses. Baloxavir is approved for early
treatment of uncomplicated influenza in outpatients aged 12 years and older.
With more antiviral medications approved, recommended and available, treatment options
have improved for both hospitalized patients with severe influenza and outpatients seeking
treatment early for uncomplicated influenza. There remains a gap, however, in approved
antiviral treatment options for hospitalized patients with non-severe influenza, although CDC
and IDSA (Infectious Diseases Society of America) continue to recommend that those
patients be treated with neuraminidase-inhibitor antiviral medications.
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Decision-making tools
Risk assessment (IRAT)
The 2009 H1N1 pandemic highlighted the public health value of developing an objective,
scientifically based tool for assessing the potential pandemic risk posed to humans by
influenza A viruses circulating in animals. To fill that need, CDC developed an evaluation tool
now called the Influenza Risk Assessment Tool (IRAT) with help from global animal and human
health influenza experts. IRAT launched in 2011 and since then CDC has used it to evaluate
the potential risk posed by viruses that are not currently circulating in people. The IRAT relies
on input from subject matter experts representing a variety of expertise in the study of
influenza viruses. It uses 10 evaluation criteria grouped into major categories including
properties of the virus, attributes of the human population, and epidemiology and ecology of
the virus, to generate scores that indicate the potential risk of the virus to emerge as a
pandemic virus, and the potential impact if it does.
The IRAT is not a prediction tool. Rather, the IRAT provides structure to prioritize and
maximize investments in pandemic preparedness; identify key gaps in information; document
transparently the data and scientific process used to inform management decisions
associated with pandemic preparedness; provide a flexible means to easily and regularly
update the risk assessment of novel flu viruses as new information becomes available;
communicate effectively to the general public, policymakers, public health laboratories and
other stakeholders; and provide a means to weigh the 10 evaluation criteria differently
depending on whether the intent is to measure the ability of a virus to “emerge” as a
pandemic-capable virus, or “impact” the human population after emerging.
Since its inception eight years ago, the IRAT has been used by CDC to evaluate and inform
pandemic preparedness decisions for 16 viruses, the results of which are listed at Summary
of Influenza Risk Assessment Tool (IRAT) Results.
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Forecasting
Unlike traditional surveillance systems that lag behind the real-time situation, flu forecasting
offers the possibility to look into the future and forecast when and where flu increases will
occur, how large the impact of flu will be, and when flu will peak. Forecasts can inform
messaging to health care providers regarding influenza vaccination and antiviral treatment for
patients, help to prepare for an influx of illnesses and hospitalizations, and be used to guide
community mitigation strategies, such as school closures.
To support the development of the science of flu forecasting and its application for public
health, CDC, through the Epidemic Prediction Initiative (EPI), organized the first FluSight
challenge to forecast the timing, intensity, and short-term activity of the influenza season
during the 2013-14 season. Each influenza season since then, Influenza Division researchers
have worked with CDC’s EPI and other external researchers to improve flu forecasting. CDC
provides forecasting teams data, relevant public health forecasting targets, and forecast
accuracy metrics evaluated against actual flu activity while each team submits their forecasts
based on a variety of methods and data sources each week. During the 2018–19 season,
forecasting teams provided over 30 national-level forecasts each week.
These challenges have provided the scientific and public health community with experience in
real-time forecasting, the ability to evaluate forecast accuracy, and familiarity in
communicating and applying these forecasts in real-world settings. These experiences are
critical to developing a network of forecasters capable of providing results that public health
officials can use, both in seasons and during an influenza pandemic.
Forecasts are currently used to inform CDC’s activity summaries provided to public health
officials and CDC leadership, and to inform messages to the general public regarding the
timing of the influenza season and steps the public can take to protect their health.
Top of Page
International work
CDC has strong global ties with other WHO Collaborating Centers for Influenza, National
Influenza Centers and ministries of health around the world. These collaborators provided
critical data throughout the influenza pandemic on how, when and where the pandemic virus
might be changing and if the monovalent pandemic vaccine would continue to be effective in
preventing infection.
CDC’s Influenza Division formed an influenza international capacity-building initiative in 2004,
which provided a five-year period of financial support for nine countries to improve laboratory
diagnostics and sentinel surveillance for influenza-like illness and severe acute respiratory
infection. In 2009, this number increased to 37 countries receiving support under 39
cooperative agreements.
Thus, the 2009 H1N1 pandemic occurred at a time when many of the 37 countries benefited
from the newly established influenza surveillance and laboratory capacities. The pandemic
provided the ultimate test to determine whether their laboratory diagnostics and surveillance
systems were indeed strong enough to manage the massive surges in flu activity that would
come their way.
Shortly after the pandemic, eight of the 37 countries transitioned to the program’s second
five-year period, called the sustainability period. During this period, financial support was
reduced as the programs focused on sustaining the gains made in laboratory diagnostics and
surveillance. The countries focused on standardizing foundational aspects of influenza
surveillance including regular influenza activity reporting and sending viruses to CDC and
other WHO Collaborating Centers, all with an eye toward ensuring preparedness for the next
pandemic.
Now, following 10 years of the pandemic’s race around the globe, which caused hundreds of
thousands of deaths worldwide, many countries have graduated from the sustainability period
to maintenance and some are now developing in-country seasonal influenza vaccination
programs based on their influenza surveillance data.
The 2009 H1N1 pandemic tested U.S. laboratory and surveillance systems and highlighted
many successes along the way, shining a light on one of the biggest takeaways of the 2009
H1N1 pandemic: develop seasonal influenza epidemiology and laboratory capacity that’s
flexible enough to handle the next pandemic.
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